|Bid price||178.50||Open price||178.90|
|Ask price||179.20||Prev close||179.20|
Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.
Register now for FREE Vectura Group share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B01D1K48|
|Activites||Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.||Index||FTSE 250|
|Latest Share Price (p)||179.20||Net Gearing (%)||-6.27|
|Market Capitalisation (£m)||720.24||Gross Gearing (%)||24.40|
|Shares in issue (m)||404.52||Debt Ratio||10.20|
|P/E Ratio||197.83||Debt-to-Equity Ratio||0.35|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.32|
|Dividend Yield (%)||0.00||Price to book value||3.25|
|Dividend cover (x)||0.00||ROCE||-0.03|
|Earning per share (p)||0.90||EPS Growth (%)||228.57|
|52 week high / low||183.75 / 113.75||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|17/04/2015||EXR||Dr Christopher Blackwell||RES||18,987|
|16/01/2015||EXR||Dr Trevor Phillips||ED||3,133|
|16/01/2015||EXR||Dr Trevor Phillips||ED||208,877|
|16/01/2015||SEXR||Dr Trevor Phillips||ED||171,777|
|08/07/2014||BUY||Dr Christopher Blackwell||RES||1,212|
/* */ RNS Number : 7314R Vectura Group plc 01 July 2015 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 1 July 2015: In accordance with the Financial Conduct Authority's Transparency...
/* */ RNS Number : 3743R Vectura Group plc 26 June 2015 For filings with the FCA include the annex For filings with the issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i...
Vectura Group (LSE: VEC), which specialises in the development of products for the treatment of airways-related diseases, has appointed James Ward-Lilley as CEO. He will succeed Dr Chris Blackwell who, as previously announced, leaves Vectura at the end of this month. Mr Ward-Lilley will join...
Register now for FREE Vectura Group company news